InMed Pharmaceuticals

Company snapshot

InMed Pharmaceuticals is a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. InMed’s pipeline consists of three drug development programs in the treatment of Alzheimer’s, ocular and dermatological indications. Together with our subsidiary BayMedica, we are a global leader in the manufacturing, development and comm

• 1 active pipeline program(s) linked via ClinicalTrials.gov.
• 15 US patent(s) indexed to this assignee profile.
• 1 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for InMed Pharmaceuticals. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for InMed Pharmaceuticals.

1. May 23, 2026 Clinical update

   INM-755 (cannabinol) cream — Phase 2

2. Jul 15, 2025 Patent grant

   Topical formulations of cannabinoids and use thereof in the treatment of pain

3. Sep 10, 2024 Patent grant

   Ocular drug delivery formulation

4. Jul 23, 2024 Patent grant

   Use of topical formulations of cannabinoids in the treatment of epidermolysis bullosa and related connective tissue disorders

5. Oct 18, 2022 Patent grant

   Acetylcholine receptor-binding peptide

View all clinical trial activity →

• What is InMed Pharmaceuticals?

  InMed Pharmaceuticals is a pharma organization headquartered in Vancouver, CA. It trades on NYSE under ticker INM. Primary therapeutic focus areas include Epidermolysis Bullosa Simplex. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 15 patent record(s) to this

• Is InMed Pharmaceuticals publicly traded?

  Yes. InMed Pharmaceuticals is listed with ticker INM on NYSE per SEC EDGAR records linked on this profile.

• What drugs does InMed Pharmaceuticals develop or market?

  No drug profiles are currently linked to InMed Pharmaceuticals. Pipeline programs may still list investigational assets.

• What are the latest developments for InMed Pharmaceuticals?

  In the last 12 months our linked public records show 1 trial program update(s) and 1 US patent grant(s) tied to this profile.

• What therapeutic areas does InMed Pharmaceuticals focus on?

  InMed Pharmaceuticals focuses on Epidermolysis Bullosa Simplex based on our analysis of their pipeline programs and drug development activities.